Alimera Sciences Announces Multiple Posters and Papers Highlighting the Durability of ILUVIEN® To Be Presented at the EURETINA 2020 Virtual Congress


ATLANTA, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that clinical data for ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19mg will be featured in over 20 papers and presentations during the EURETINA 2020 Virtual Congress, to be held on October 2-4, 2020.

Go here to see the original:
Alimera Sciences Announces Multiple Posters and Papers Highlighting the Durability of ILUVIEN® To Be Presented at the EURETINA 2020 Virtual Congress

Related Posts